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Bullous pemphigoid (BP) is an autoimmune blistering skin 
disease characterized in part by the presence of circulating 
and tissue-bound IgG antibodies directed against the epider-
mal basement membrane zone. IgG from over 95% of pa-
tients -with BP have been shown to immunoprecipitate a 
230-kD epidermal protein, BPAgl, which has been cloned 
and sequenced. Although sera from almost all patients with 
BP react -with the 230-kD BP antigen the specific epitope(s) 
of BPAgl that IgG binds is not known. We have generated 
fusion proteins from the 230-kD BP antigen cDNA and 
analyzed sera from patients with BP for binding to these 
fusion proteins by immunoblot. Sera from 21 of 30 (70%) 
patients "With BP reacted with FP3A (amino acid 873-1193) 
compared to four of 13 (30%) normal subjects (p < 0.02). 
Sera from 10 of 30 (33%) patients reacted with FP7 
(AA1623-1812) and to FP3 (AA1003-1193), compared to 
B ullous pemphigoid (BP) is an autoimmune blistering skin disease characterized in part by the presence of IgG autoantibodies that bind in a linear pattern at the basement membrane zone of stratified squamous epi-thelium [1-4]. These IgG autoantibodies may be de-
tected in the skin of up to 90% of patients with BP and in the serum 
of 65 - 80% of patients with active disease [1,2]. Although the ma-
jority of patients with BP have IgG antibodies reactive against nor-
mal human skin, no consistent correlation has been demonstrated 
berween anti-basement membrane zone antibody titer and disease 
activity or prognosis [1,2,5 ,6]. One potential explanation o~ this 
observation is that the anti-basement membrane zone auto-antibod-
ies react with epitopes on the BP antigen{s) present on the normal 
human skin substrate used in indirect immunofluorescence, which 
are not associated with the development of clinical disease activity 
or its severity. To further understand the role of these anti-basement 
membrane zone autoantibodies in the pathogenesis and clinical 
manifestations ofBP it will be necessary to determine the autoanti-
body binding epitopes on the BP antigen{s). 
Over the past decade two major antigenic targets recognized by 
IgG from patients with BP have been identified: a 230-kD protein 
and a 180-kD protein [7 -1 0]. Greater than 95% of patients with BP 
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o.ne ?f22 (5%) .a~d 0 of 19 (0%) controls, respectively. No 
sl~l11ficant reactivity was noted against two other fusion pro-
tems (FP6, FP9). Twenty-four of 30 (80%) patients with BP 
reacted to at least one of three fusion proteins (FP3, FP3A, 
FP7) compared to three of 11 (27%) of the control subjects 
(p < 0.003). Fusion proteins FP3, FP3A, and FP7 are at the 
amin~- or c~rboxyl.-terminal regions of the putative central 
a-helical cOIled-coil rod domain ofBPAgl, which has been 
postulated .to be involved in the self-aggregation of BPAg!. 
These. findmgs ~emonstrate that patients with bullous pem-
plugOid react with multiple regions of BPAg1 and suggest 
that. pa:t of t~e pathologic consequences of these auto-anti-
b?dles ~n patients with bullous pemphigoid may be by the 
disruption of the normal self-aggregation of the BPAg!. 
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immunoprecipitate the 230-kD BP antigen, which has been im-
mun.olocahzed to the intra-cellular hemidesmosomal region of 
stratified squamous epithelium [7 -11]. The 230-kD BP antigen 
(BPAg1) has been cloned and sequenced and found to have signifi-
cant ho~ology . to. desmoplakin I [8,12,13]. This homology has 
resulted 111 predictIOns that the central alpha helical coiled-coil re-
?ion m~y be important in self-aggregation of the BPAg1 and in 
1I1teractIOns of BPAg1 with keratin filaments [13]. 
In thiS study we have used overlapping cDNA clones of the 
230-kD BP antigen BPAgl to generate 190-320 amino acid fusion 
proteins encoded fo: ~y the central a-helical coiled-coil region of 
the molecule. ReactiVity ofIgG from patients with BP and normal 
subjects to these fusion proteins was detected using immunoblot 
analysis. Fusion proteins were also used to immunize rabbits and the 
resultant antibodies were tested for reactivity against normal human 
skin. We have found that 80% of patients react with two distinct 
regions.of the central region of the BPAg1 located at the carboxyl 
and ammo ends of t.he central a-helical coiled-coiL This data sug-
gests that these regIOns near the amino and carboxyl ends of the 
putative ~-helical coiled-c.oiled rod-like domain of the BPAg1 may 
have particular relevance m the pathogenesis of BP. 
MATERIALS AND METHODS 
Patients Sera from 30 patients with BP were studied. All patients had 
typical clinical and histologic findings of BP. Direct immunofluorescence 
revealed a linear band of C3 at the basement membrane zone in all patients 
studied. Sera from nine patients with other blistering diseases were also 
studied (cicatricial pemphigoid, three; pemphigus vulgaris, three; dermatitis 
herpetiformis, three). Sera from 22 blood bank donors were used as normal 
controls. 
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Figure 1. Schematic representation of the 230-kD BP antigen BPAgl. The relative locations of the fusion proteins studied are noted as is the central a-helical 
coiled-coil rod domain. Amino acid numbering is as described by Sawamura eC a( [12J. 
Fusion Protein Production Overlapping cDNA encoding the 230-kD 
BP antigen were obtained as a gift from Dr. John Stanley, Dermatology 
Branch, National Cancer Institute. Twenry-four to twcnry-five 
nucleotide - long primers containing either Bam HI, Eco Rl, or Sma1 re-
striction enzyme recognition sequences were used to specifically amplify 
500 - 1000-bp fragments of various BPAgl cDNA using the polymerase 
chain reaction (PCR) (Fig I, Table I). 
Approximately 20 J1g of the individual amplified DNA fragments was 
digested with the appropriate restriction enzymes and directionally cloned 
into the pGEX2T vector (Pharmacia, Piscataway, NJ). Ligated clones were 
used to transform BL21 Escherichia coli cells. Transformants were isolated on 
plates containing 50 J1g/ml of ampicillin. Transformants were induced to 
produce protein as described by the manufacturer and the presence of the 
appropriate-sized fusion protem was confirmed by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). 
Large-scale production of fusion proteins was then undertaken using 
transformants shown to be producing the appropriately sized fusion protein. 
Desired transformants were grown in 100 ml Luria Bertani (LB) broth at 
37 · C overnight, then transferred to 1000 ml LB broth and grown at 32·C 
for 1 h. Protein production was induced by adding isopropyl-p thiogalacto-
side (IPTG) to 0.1 mMol and incubating another 2-3 h at 32· C. Cells were 
pelleted and resuspended in phosphate-buffered saline (PBS), pH 7.4(PBS) 
plus 1mM ethylenediaminetetraacetic acid and 0.25 mM phenyl methyl 
sulfonyl fluoride (PMSF), then lysed by sonication. After centrifugation the 
soluble fraction was passed over a column of glutathione coupled to sephar-
ose beads. The column was then washed with 20-30 ml PBS. The fusion 
. protein was eluted with an excess of reduced glutathione in 0.5 mM Tris, pH 
8.0, to recover the desired fusion protein coupled to glutathione-S-transfer-
ase (GST). Alternatively, the fusion protein was separated from the GST 
moiery by cleavage at a specific thrombin cleavage site at the junction of the 
GST l110iery and the expressed BPAgl protein, by adding a thrombin/Ca-l+ 
solution (50 roM Tris-HCI, pH 7.5,. 150 mM NaCI, 1 mM CaCI2, and 
50 J1g thrombin) directly to the column and incubating at room temperature 
for 2 h [14J. The freed 190-320 amino acid fusion protein was eluted from 
the column and the recovery confirmed by SDS-PAGE. 
Immunoblot Analysis Fusion proteins were separated on 12% SOS-
PAGE and electrophoretically transferred onto nitrocellulose paper as previ-
ously described (11]. Success of transfer was confirmed by staining of control 
strips of nitrocellulose with amido black. The remaining nitrocellulose was 
blocked for 2 h in 10 mM Tris 0.15 M NaCI (TBS) buffer containing 1% 
milk solids. The nitrocellulose was then cut into strips and each strip was 
incubated overnight in sera from patients with BP or normal blood bank 
donors. Sera were diluted 1: 50 in TBS containing 1% Tween-20 (TBS-
Tween). The strips were washed (three times,S min each time) and incu-
bated for 30 min in a 1 : 7500 dilution of alkaline-phosphatase-conjugated 
goat anti-human IgG then developed with NBT /BClP color developer for 
Table I. Immunoblot Reactivity of Sera from Patients with BP 
and Normal Subjects Against Fusion Proteins Encoded by the 
230-kD BP cDNA 
Fusion Protein BP 
FP 9 (683-853)· 3/20 (15%)h 
FP3A (873-1193) 21/30 (70%)' 
FP3 (1003-1193) 10/30 (30%)' 
FP6 (1303-1472) 1/20 (5%) 
FP7 (1623-1812) to/30 (30%)' 
• Fusion protein designation (amino acid range, BPAgl). 
I Number of subjects reactivc/toUI subjects tested (% positivc). 
, P < 0.02, Fisher's exact test, patients versus controls. 
Normal Subjects 
2/10 (20%) 
4/13 (30%) 
0/19 (0%) 
1/10 (10%) 
1/22 (5%) 
2 -:- 5 min (P~omega, ~adison, WI): Alter~atively, the stri~s were incubated 
With perOXidase-conJugated aflil1lry-punfied, heavy-ch~n-specific goat 
anti-human IgG (1: 500) (Tago, Burlmgame, CA) antibodies in TBS. 
Tween buffer a?d developed using 4-chloronapht~yl in the presence ()f 
hydrogen perOXide. RabbIt sera were tested m a sllmlar manner using, as a 
second-step antIbody, perOXidase-conJugated aflilllry-purified goat anti. 
rabbit IgG antibodies (Tago Inc, Burlingame, CA) diluted 1: 1000 in TBS. 
Tween buffer and developed using 4-chloronaphthyl in the presence of 
hydrogen peroxide. 
Rabbit Antibody Produc~ion Female New Z~aland wh.ite rabbits (4-6 
pounds each) were Immunlzed With 1 mg of fUSIOn protem, either FP3. 
F~7-, or FP9-G.ST fusion proteins or with GST alone, in Freund's comple~ 
adJuvaI~t . RabbIts were .boosted at weeks 2 and ~ with 0.7 mg protein in 
~reund.5 IIlcompl.ete adjuvant. The presence of Clrculatmg antibody to th~ 
lmmumzed protem was confirmed by Immunoblot as described above. 
Indirect Immunofluorescence Sections of normal human 1 M N aCJ 
s~ lit skin prepared ~s previously ?escribed were incubated for 30 min with 
either pre- or post-Immune rabbltsera diluted 1 :SO in PBS [15J. Sections 
were then was~ed a~d counterst~med With affimry-purified FITC-conju. 
gated, goat anti-rabbit IgG and Viewed usmg a fluorescence microscope. 
RESULTS 
Reactivity of Sera from Patients with BP Antibody Against 
Fusion Proteins Encoded by the 230-kD BPAgl cDNA FiVe 
fusion proteins have been successfully produced and analyzed for 
antibody binding using serum from patients with BP: FP3A, 3, 6,7 
and 9 (Fig 1, Table I). These fusion proteins span the region of 
BPAgl extending from amino acid 683 to 1812, encompassing the 
region of the BP Ag1 thought to be an a helical coiled-coil rod (AA 
875-1813) (Fig 1). 
Sera from 21 of30 (70%) patients with BP bound by immunoblo( 
to FP3A (AA 873-1193) compared to sera from four of 13 (30%) 
blood bank controls (p < 0.02, Fisher's exact test) (Table I and Fig 
3). To further characterize reactivity to this region of the molecule a 
truncated fusion protein FP3 (AA 1003-1193), was produced that 
did not include the initial 130 amino acids at the amino end of the 
fusion protein FP3A. Serum from 10 of 30 (33%) patients with BP 
bound to FP3 by irnrnunoblot compared to 0 of the 19 (0%) blood 
bank controls (p < 0.004, Fisher's exact test) (Fig 2). All sera from 
patients with BP that ~ound ~o FP3 .also bound t~ FP3A (Fig 3). 
None of the sera from nme patients With other autOImmune blister_ 
in& sk~n diseases (thre~ .pemphi&us vu}garis, three cicatricial pelll. 
phi gOld, three dermatltls herpetlfofllllS) bound to FP3. Significant 
reactivity was also found to FP7 (AA 1623-1812), a 189-amino 
acid protein from the carboxyl end of the a-helical coiled-coil rod 
region ofBPAg1. Sera from 10 of30 (33%) patients with BP bound 
to FP7 compared to one of22 (5%) blood bank controls (Table I and 
Fig 3) (p < 0.002, Fisher's exact test). 
No significant reactivity was seen against either fusion proteins 
FP6 (one of 20 [5%J patients with BP) or FP9 (three of 20 [15%), 
patients with BP) (Table I and Fig 3). FP9 (AA 683-853) is located 
just outside the amino terminus end of the coiled-coiled rod do-
main, whereas FP6 (AA 1303-1472) is located in the mid-portion of 
this region (Fig 1). 
Twenty-one patients were evaluated for reactivity against FP3, 
FP3A, and FP7. Sera from 24 of 30 (80%) patients with BP showed 
reactivity against at least one of these three fusion proteins (Fig ). 
with four of 30 (13%) reacting with all three fusion proteins. In 
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FigUre 2. Irnmunoblot reactivity of patients with BP with FP3. LOfles 1-4, 
binding using serum from individual patients with BP; lafles 5 - 7, binding 
using serum from normal blood bank controls; lanes 8 -1 0, amino black 
staining of FP3 (lafle 8, molecular weight is 21 kD), CST alone (lalle 9, 
lllolecularVlreight is 27.5 kD), and molecular weight standards (lafle 10). FP3 
is identified by serum from patients with BP but not normal control serum. 
contrast, sera from three of 11 (27%) blood bank controls reacted 
with at least one of the fusion proteins, two of which reacted with 
FP3A. This difference was statistically significant (p < 0.003, 
Fisher's exact test). Sera from 16 of 30 (53%) patients with BP 
reacted with either the truncated fusion protein, FP3 or FP7, com-
pared to one of 19 (5%) of normal blood bank con trols (p < 0.0005, 
Fisher'S exact test) (Fig 3). 
No significant differences were noted between patients with BP 
that reacted with the fusion proteins tested and those that did not as 
determined by clinical presentation, disease severity, or response to 
therapy. 
Antibody Production in Rabbits To determine if these fusion 
proteins m.ight contain epitopes that would result in antibodies di-
rected against epitopes present on the native BPAg1 of human epi-
dermal basement membrane zone, rabbits were immunized with 
FP3-, FP7 - , FP9-GST fusion proteins or with GST alone. Rabbits 
immunized with the fusion proteins FP3-GST and FP7-GST, but 
not with FP9-GST or the GST control protein, produced IgG anti-
bodies that bound to the roof of the basement membrane zone of 
normal human 1M NaCI split skin in a pattern similar to that seen 
with sera from patients with BP. Serum from all immunized rabbits 
reacted with GST by immunoblot (data not shown). 
DISCUSSION 
We have generated fusion proteins representative of the central, a 
helical coiled-coil rod region of BPAg1 and the adjacent flanking 
regions and used them in immul1oblot assays with sera from patients 
with BP and normal subjects. Of the five fusion proteins we have 
produced and analyzed, FP3, FP3A, and FP7 demonstrate disease-
specific .anti~ody bindi~g. Seventy percent of patients with BP had 
antibodies directed agall1st FP3A compared to 30% of normal sub-
jects (p < 0.02, Fisher's exact test) (Table I, Fig 1). Deletion of130 
amino acids from the amino portion of this protein, FP3, decreased 
the frequency of reactivity with sera from both normal subjects (0 of 
19) and patients with BP (10 of 30, 33%). The specificity of the 
interaction of sera from patients with BP and FP3 is demonstrated 
by the lack of binding of sera from patients with other blistering 
skin diseases to FP3. In a similar manner, sera from 48% of patients 
with BP showed specific reactivity with FP7 compared to only 7% 
of the control subjects tested. No reactivity was seen using sera from 
either patients with BP or normal subjects to either FP6 or FP9. 
When the data were analyzed for binding to either fusion protein 
3, 3A, or 7, sera from 80% of patients with BP studied showed 
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reactivity against at least one of these three proteins, compared 
to three of 11 sera from controls. These fusion proteins, FP3A, 
FP3, and FP7, w~re from. the amino (FP3 and FP3A) and the car-
boxyl (FP7) termlI1al regIOns of the a-helical, coiled-coil rod do-
main (Fig 1). The fusion proteins to which the BP sera did not bind 
were localized ju~t outside of the amino portion of the a-helical 
regIOn, FP9, and 111 the mid-portion of the coiled-coil, FP6. 
When the fusion proteins FP3, FP7, and FP9 were used to immu-
nize rabbits, antibodies that bound the basement membrane zone of 
normal human skin were produced in the rabbits immunized with 
FP3 and FP7, but not FP9. This suggests that epitope(s) are present 
m FP3 and FP7 that are also accessibJe in the basement membrane 
zone of normal human skin as it is utilized for IDIF. 
One finding of i~terest is the relatively large number of normal 
subjects ~ho have clrcu.lating .antibodies th.at reac: with FP3A (four 
of 13,31 Yo) . These patle.nts did not have clfculatl11g anti-basement 
membrane zone antibodies detected using IDIF on 1 M NaCI split 
~1Um~n sklI~ (da.ta not shown). Further investigation of these sub-
Jects l11cludll1g Immunoprecipitation ~f cultured ker~tinocytes ex-
tra~ts and companson of the. exact regIOns of the fUSIOn protein to 
whICh sera from normal subjects and BP patients bind will need to 
be perfor~ed to more completely understand this observation. 
AnalySIS of the DNA sequence ofBPAg1 has revealed significant 
5% 
1/10 
10% 
positive 
Negative 
2/10 
20% 
Not Tested 
Figure 3. Iml11ul1oblot reactivity of sera from patients with BP with fusion 
proteins encoded by the 230-kD BP antigen (BPAgl) eDNA. 
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homology between BPAg1 and desmoplakin I, suggesting that both 
of these proteins are part of a new family of adhesion plaque proteins 
and that the central a helical coiled-coil rod domain may playa role 
in self-aggrega tion of the BPAgl and the interaction of BPAgl 
with intermediate filaments within the cell [12,13]. We would 
speculate that disruption of this rod-like structure by antibody bind-
ing could disrupt the function of BPAg1. This disruption could 
potentially be a factor both in the induction of blistering and/or the 
healing of lesions that are present in patients with BP. Further 
epitope mapping of this region and functional studies may provide 
important information regarding the normal function of BPAg1 
and of the mechanisms of epidermal adhesion. 
Despite the high frequency of reactivity of BP patients' sera to 
FP3A and FP7, it is clear that other areas of the BPAg1 are also 
important in the pathogenesis of BP. Fusion proteins from the 
mouse BP antigen have been utilized to demonstrate that the region 
that includes the carboxyl portion of the a-helical rod domain is 
recognized by 63% of patients with BP and that fusion proteins that 
were outside of this region of the molecule also reacted with sera 
from 35% of patients with BP [1 6]. Tanaka et al have demonstrated 
that rabbit antibodies directed against the region ofBPAg1 located 
just outside the carboxyl terminal end of the a-helical rod region 
were able to bind to the basement membrane zone of human skin 
[11] . Similarly, Rico and co-workers have demonstrated that 38% of 
patients with BP reacted to synthetic peptides encoded by the region 
just outside the a-helical rod region, but not to syntheticreptides 
within the a-helical rod region that contains FP7 [17 . These 
previous observations along with our current data suggest that anti-
bodies against BPAgl react with multiple epitopes, consistent with 
an antigen-driven immune response. It still remains to be demon-
strated if any of these regions or others yet undetected are of 
particular significance as the potential initiating si tes of the 
immune response or as potential markers of disease severity or ac-
tivity. 
It is also important to note that studies performed to date have for 
the most part utilized techniques that recognize sequential or linear 
epitopes on the BP antigen{s}. Conformational epitopes, however, 
which are not detected with either synthetic peptides or immuno-
blot analysis, are an important site of immunoglobulin-protein in-
teractions. Such conformational epitopes may play an important 
role in the pathogenesis of BP and further studies should also be 
directed at determining these conformational epitopes of the 
BPAg1. 
In summary, we have demonstrated that 80% of patients with 
BP have circulatin g IgG that binds to fusion proteins encoded for 
by either the amino or carboxyl terminal regions of the putative 
a -helical coiled-coil rod of the BPAg1 cDNA. These fusion pro-
teins are of particular interest because this region of the molecule has 
been postulated to be important in self-aggregation of the BPAgl 
and the interaction of BPAgl with intermediate filaments. Al-
though it is clear that these are not the only regions to which 
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circulating IgG autoantibodies bind, the potential fu nctional signif-
icance of this region suggest that these antibodies may be of particu. 
lar importance in the pathogenesis of BP. Further analysis of the 
central coiled-coil region and other regions of BPAgl w ill provid~ 
important information regarding the pathogenesis of BP as well as 
provide important clues to the functio n ofBPAg1. 
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